BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - BioMarin Pharmaceutical reported $745.74 million in revenue for Q3 2024, a year-over-year increase of 28.3% [1] - The company achieved an EPS of $0.91, up from $0.46 a year ago, exceeding the consensus EPS estimate of $0.78 by 16.67% [1] Revenue Performance - Total revenue of $745.74 million surpassed the Zacks Consensus Estimate of $706.95 million, resulting in a surprise of +5.49% [1] - Royalty and other revenues were $11.87 million, slightly below the average estimate of $10.30 million, reflecting a year-over-year decline of -9.1% [3] - Net product revenues reached $733.87 million, exceeding the average estimate of $698.26 million, with a year-over-year increase of +29.1% [3] - VOXZOGO generated $190 million in net product revenues, slightly below the average estimate of $195.48 million, but showing a significant year-over-year increase of +54.4% [3] - KUVAN's net product revenues were $28 million, surpassing the average estimate of $26.40 million, but reflecting a year-over-year decline of -34.7% [3] - ROCTAVIAN's net product revenues were $7 million, close to the average estimate of $7.18 million [3] - VIMIZIM reported $178 million in net product revenues, slightly below the average estimate of $183.21 million, with a year-over-year increase of +12% [3] - BRINEURA's net product revenues were $37 million, below the average estimate of $46.24 million, indicating a year-over-year decline of -9.8% [3] - NAGLAZYME generated $132 million in net product revenues, exceeding the average estimate of $115.28 million, with a year-over-year increase of +21.2% [3] - PALYNZIQ's net product revenues were $91 million, slightly above the average estimate of $89.95 million, reflecting a year-over-year increase of +15.3% [3] Stock Performance - Over the past month, BioMarin's shares returned -0.2%, while the Zacks S&P 500 composite increased by +1.7% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]